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ABSTRACT 
The neuroleptic drug thioridazine has been recently repositioned as possible anti-tubercular 
drug. Thioridazine showed anti-tubercular activity against drug resistant mycobacteria but it is 
endowed with adverse side effects. A small library of thioridazine derivatives has been 
designed through the replacement of the piperidine and phenothiazine moieties, with the aim 
to improve the anti-tubercular activity and to reduce the cytotoxic effects. Among the resulting 
compounds, the indole derivative 12e showed an antimycobacterial activity significantly better 
than thioridazine and a cytotoxicity 15-fold lower. 
1. INTRODUCTION
According to the recent World Health Organization annual report, tuberculosis (TB) remains 
one of the deadliest communicable infections.[1] Nearly one third of the worldwide population 
is latently infected with Mycobacterium tuberculosis (MTB), the etiological agent of 
tuberculosis in humans, and almost 9 million people develop active TB infections per annum. 
In addition, 14.8% of global TB patients are co-infected with HIV and can be credited as one 
of the most common causes of death among AIDS patients.[2,3] This global scenario is due to 
many causes including the lack of rapid diagnostic tools, the non-compliance of hospitalised 
patients to the 6-12 months multidrug therapy and institutions lacking the proper drug regimens 
to treat all the people infected.[4] As a consequence of these transgressions, and after half a 
century of little to no innovation in the field, MTB have developed multi-drug resistant 
(MDR),[5-7] extensively-drug resistant (XDR) [8] and totally-drug resistant (TDR) [9] strains, 
which are resistant to almost all the known available drugs. In 2012, the quinoline derivative 
bedaquiline [10-11] became the first new drug launched in the market in the last 40 years, since 
the discovery of rifampin. Currently a number of lead molecules are in clinical trials, such as 
the diamine SQ109,[12] the fluoroquinolone gatifloxacin [13] and the linezolid.[14] However, 
the conventional therapeutic approach potentially exacerbates the incidence of new MDR-TB 
strains and therefore it is inevitable that MTB will evolve resistance against these novel 
drugs.[15-16]  
Conventional drug discovery approaches need the identification of a specific target for the 
development and optimization of a specific molecule. However, it is well known that singular 
mutations of the targets active site could result in the nullification of drug activity.[17] The 
current treatment of TB involves the administration of several drugs simultaneously, this 
reduces the incidence of resistant MTB strains by avoiding single point mutations resistances 
against singular treatments. However, several side effects and poor patient compliance are 
associated with the present multiple therapy. A potentially successful approach to defeat TB is 
to discover a drug capable of inhibiting multiple MTB targets simultaneously whilst also 
retaining activity against MDR and latent TB with an ultimate objective of shortening the 
current TB regimens.  
Thioridazine (TZ) 1, a long established neuroleptic drug, has been recently repositioned as anti-
tubercular drug finding application in the treatment of MDR-TB.[18-19] TZ is currently used 
in therapy as a third line anti-tubercular drug due to the side-effects on the central nervous 
system and cardiovascular system which restrict its clinical use.[20] Despite the mechanism of 
action of TZ having not been fully elucidated, recent studies showed that it inhibits efflux 
pumps in mycobacteria and alters the cell-envelope permeability of MTB.[21-23] Furthermore, 
TZ 1 is able to affects the physiology of alveolar macrophages, enhancing the retention of 
potassium ions and promoting the acidification of phagolysosomal vacuole,[24] finally leading 
to the degradation of intramacrophagic MTB.  
Despite the chemistry and structure-activity relationship (SAR) properties of TZ, and related 
neuroleptic drugs, having been widely investigated in the past, to the best of our knowledge no 
drug derivatization and optimization studies have been carried out on TZ analogues as 
inhibitors of MTB. 
Herein, we report the synthesis, biological evaluation and SAR studies of a narrow library of 
novel TZ derivatives. In particular, we aimed at the design and identification of novel TZ 
analogues with improved activity against TB and MDR-TB strains as well as reduced cytotoxic 
effects. Three series of derivatives were planned in order to explore the chemical space around 
the TZ nucleus, as shown in Figure 1. In the first series, the N-methyl substituent on the 
piperidine ring was removed or replaced with different alkyl groups to evaluate its importance 
for anti-tubercular activity. In the second series, the piperidine ring of TZ was replaced with 
different aliphatic heterocyles, keeping fixed the distance between the piperidine nitrogen and 
the phenothiazine ring. 
Figure 1. General structures of the thioridazine analogues 
The role of the thiomethyl group attached to the phenothiazine ring was also investigated in 
this series. Finally, in the third series the phenothiazine core, which is responsible for the main 
side effects on the nervous system, was replaced with different heteroaromatic rings, with the 
aim to reduce the toxicity of the molecule.  
2. RESULTS AND DISCUSSION
2.1 Chemistry 
Scheme 1. Synthesis of analogues 4a-c. Reagents and conditions: i. 1-chloro-ethyl-
chloroformate, DCE, Et3N, reflux, 12 h; ii. MeOH, reflux, 12 h; iii. NaBH(AcO)3, THF, AcOH, 
benzaldehyde for 4a, or propionaldehyde for 4b, or acetone for 4c. 
A series of N-substituted derivatives 4a-c was first synthesised. TZ was successfully 
demethylated by treatment with 1-chloro-ethyl-chloroformate in refluxing DCE [25] followed 
by hydrolysis with MeOH under reflux, leading to derivative 3. Reductive amination of 3 with 
different aldehydes/ketones led to the final N-alkyl-derivatives 4a-c in good yields (62-68%). 
Scheme 1.  
Table 1. Synthesis of the compounds 7a-i and 9a-b. 
Reagents and conditions: i. 1-bromo-3-chloropropane, NaH, DMF, r.t., 12 h; ii. amine, 
Et(iPr)2N (DIPEA), NaI, DMF, 150 °C, 3 h; iii. 2-chloroacetyl chloride, NaH, DMF, r.t., 12 h; 
iv. amine, NaH, DMF, 150 °C.
Cmpd R Amine/R1 Cmpd R 
7a H 7g SMe 
7b H 7h Cl 
7c SMe 7i Cl 
7d SMe 9a SMe 
7e SMe 9b SMe 
7f SMe 
A second series of derivatives where the piperidine ring was replaced with different piperazine 
and thiomorpholine groups was then synthesised (Table 1). In addition, the thio-methyl 
substituent on the phenothiazine ring was removed or replaced with chlorine, to evaluate its 
importance for the anti-tubercular activity.  
In particular, the chlorine substituent was chosen on the basis of similarity with 
chlorpromazine, a phenothiazine derivative closely related to TZ whose efflux pumps 
inhibitory activity is well known. In detail, the phenothiazines 5a-c were first reacted with 1-
bromo-3-chloropropane to yield the chloroderivatives 6a-c which were in turn treated with 
different piperazines and with thiomorpholine to yield the desired products 7a-i. The thio-
methyl-phenothiazine 5a was also reacted with 2-chloroacetyl chloride leading to 8, which was 
in turn converted into derivatives 9a-b by treatment with methylpiperazine or piperidine. 
Scheme 2. Synthesis of analogues 12, 13 and 16. Reagents and conditions: i. (Boc)2O, 
Na2CO3(aq)/DCM, r.t., 12 h; ii. PPh3, CBr4, DCM, r.t., 2 h; iii. Heterocycle, NaH, NaI, DMF, 
r.t., 12 h; iv. HCl/EtOAc, r.t., 24 h; v. CH2CO, NaBH(AcO)3, THF, AcOH, r.t., 24 h; vi.1-bromo-
3-chloropropane, NaH, DMF, r.t., 12 h; vii. N-methyl-piperazine, Et(iPr)2N (DIPEA), NaI,
DMF, 150 °C, 3 h.
Finally, the third series of compounds bearing the ethyl-piperidine chain of TZ bound to 
different aromatic heterocycles was synthesised. Scheme 2. 2-(Piperidin-2-yl)ethanol 10 was 
converted into the Boc-bromoderivative 11 by treatment with (Boc)2O followed by reaction 
with CBr4. Different heteroaromatic compounds (namely phenothiazine, 2-Cl-phenothiazine, 
carbazole, indole, and benzimidazole) were then alkylated with 11 and the resulting 
intermediates were deprotected with TFA yielding the 12a-e series of compounds. N-
methylation of 12 through reductive amination led to the methyl derivatives 13a-d.[26] Finally, 
16, bearing an indole nucleus and a piperazine ring as the aliphatic side chain, were synthesised. 
Indole 14 was converted into the N-chloro-propyl derivative 15, which yielded the final 
compound 16 after treatment with N-methyl-piperazine. 
2.2. Biological evaluation 
All the compounds were initially evaluated for their activity against a panel of non-pathogenic 
mycobacteria strains (namely, M. smegmatis mc2155, M. bovis BCG and M. tuberculosis 
mc27000, as shown in Table 2).  
Table 2. Activity of TZ derivatives on mycobacterium species (expressed as g/mL). 
Cmpd 
M. smegmatis
mc2 155
M. bovis
BCG
M. tuberculosis MDR-TB 
mc27000 H37Rv 
Susc. 
(CF73) 
CF104 CF81 
TZ 1 16 16 8 10 8 11 10 
3 16 8 8 100 >100 >100 >100
4a 16 8 8 >100 37 32 44
4b >64 64 64 45 - - -
4c >64 >64 >64 - - - - 
7a 64 64 27 100 >100 >100 >100
7b >64 >64 >64 - - - - 
7c 32 8 27 69 27 23 33 
7d >64 >64 >64 - - - - 
7e >64 >64 >64 - - - - 
7f 64 64 64 - - - - 
7g 4 >64 >64 43 98 20 48 
7h >64 >64 >64 - - - - 
7i >64 >64 >64 - - - - 
9a >64 >64 >64 - - - - 
9b - - - >100 >100 72 >100
12a >64 >64 >64 >64 47 >64 58 
12b 16 5.3 4 26 11 19 11 
12c >64 >64 >64 - - - - 
12d >64 >64 >64 100 >100 >100 >100 
12e 1.6 64 - 2.9 1 10 4 
13a 32 64 16 >64 47 >64 58 
13b 16 8 8 19 16 16 12 
13c >64 >64 64 60 39 48 46 
13d >64 >64 >64 - - - - 
16 >64 >64 >64 - - - - 
INH 4 0.063 0.125 0.03 0.03 >25 >25 
RIF - - 0.25 0.3 8 >25 >25 
 
A SAR analysis showed that removal of the methyl group of thioridazine did not affect the 
activity, the desmethyl-thioridazine 3 showing an activity similar to that of 1. Also the 
introduction of a benzyl chain as in 4b maintained a similar activity. On the other hand, the 
replacement of the piperidine-ethyl moiety with alkyl chains bearing piperazine or 
thiomorpholine rings as in 7 and 9 led to a dramatic decrease of antimycobacterial activity, 
with the only exception of the bulky derivative 7g which showed a MIC = 4 g/mL on M. 
smegmatis. Moreover, removal of the methylthio substituent of 1 and 3 (as in 13a and 12a), as 
well as replacement of the phenothiazine scaffold with different heterocyclic moieties (as in 
13c-d and 12c-d) led to a significant loss in activity.  
 
Table 3. Cytotoxicity of compounds 1, 12b, 12e, 13b expressed as g/mL and Selectivity Index 
expressed as absolute number 
Cmpds IC50 MRC-5  IC50 J774 SIa 
TZ 1 8.2 g/mL 4.1 g/mL 1 
12b 10 g/mL 10.7 g/mL 0.9 
12e 15 g/mL 7.3 g/mL 15 
13b 13 g/mL 8.4 g/mL 0.8 
aSelectivity index is calculated as the ratio between the M. tuberculosis Susc. (CF73) MIC 
and the MRC-5 IC50. 
 
On the contrary, replacement of the same SMe group with a chloride group (as in 12b and 13b), 
as well as replacement of the entire phenothiazine moiety with an indole nucleus as in 12e 
resulted in compounds with an antimycobacterial activity comparable to or better than that of 
1 and 3. In particular, the chloro-phenothiazine derivative 12b showed a good activity against 
M. bovis BGC and M. tuberculosis mc27000 strains with MIC = 5.3 g/mL and 4 g/mL, 
respectively. Similarly, the methylated analogue 13b retained a 8 g/mL MIC value. 
Interestingly, the indole derivative 12e proved to be highly active against M. smegmatis with 
MIC = 1.6g/mL. 
The most promising compounds were then assayed against the pathogenic H37Rv strain, the 
drug-susceptible CF73 clinical isolate, and two MDR- clinical isolates (CF104 and CF81). Also 
in this case, 12b, 12e, and 13b showed the best results. In particular, the chloro-derivatives 12b 
and 13b had an activity toward the CF73 and the MDR strains similar to that of 1 in the same 
range of concentrations (8-16 g/mL). The indole derivative 12e proved to be the best 
compound of the series, with an increased activity against both H37Rv and CF73 strains (2.9 
and 1 g/mL, respectively, in comparison to 10 and 8 g/mL found for 1). Moreover, 12e also 
showed a similar profile against MDR-CF104 (10 vs 11 g/mL) and a slightly improved 
activity against MDR-CF81 (4 vs 10g/mL). These data suggest that the presence of a 
secondary amine on the piperidine side chains could be beneficial for the anti-tubercular 
activity, as also observed in our previous work.[27]  
Finally, to prove the effectiveness of the most active compounds, their cytotoxicity was 
evaluated on MRC-5 and J774 cells. As a result, 12e showed a selectivity index 15 fold higher 
than that of TZ on MRC-5 cells (Table 3). In addition, 12e showed also a good selectivity 
toward the J774 macrophage cells. 
Finally, the effect of TZ derivatives on the efflux pumps of the model surrogate organism M. 
smegmatis was tested in order to understand the mode of action of the new compounds. Efflux 
pump inhibition (EPI) is determined using a whole-cell-based assay which interrogates the total 
activity of the diverse sets of efflux pumps present in the cell. The EPI assay showed that some 
TZ derivatives are endowed with a good efflux pump inhibitory activity. However, there is a 
weak correlation between inhibition of bacterial growth and efflux pump inhibtion. The 
compounds 12b and 12e which showed the most promising antimycobacterial activity proved 
to be poor efflux pump inhibitors (Figure 2). These compounds could interfere with the cell-
envelope permeability, as already hypothesized for 1,[23] by means other than inhibiting efflux 
pumps. On the other hand, the piperazine derivatives 7a and 7c which did not show 
antimycobacterial activity, were found to inhibit efflux pumps better than the reference 
chlorpromazine. This indicates that these compounds have the potential to reverse multidrug 
resistance and could be promising candidates for inclusion in a combination therapy regimen 
owing to synergistic combinations.  
 
 Figure 2. Efflux pump inhibition assay. Graphs showing the accumulation of ethidium bromide 
(EtBr) within M. smegmatis cells in the presence of selected compounds and positive 
(verapamil VP and chlorpromazine CPZ) and negative (1× PBS) controls. Low to very high 
inhibition of efflux (as a representation of an increased level of EtBr accumulation) are shown 
by relative fluorescent units. The experiments were performed in triplicate (n = 3), and the 
graph is plotted using the average values obtained. 
 
3. CONCLUSIONS 
A classical medicinal chemistry approach has been applied to design and synthesise a narrow 
library of thioridazine derivatives by structural changes made on three different molecular 
portions. Antimycobacterial activity of the resulting compounds showed that the piperidine-
ethyl side chain is required for inhibit non-pathogenic, pathogenic and MDR mycobacterial 
strains. Moreover, the SMe-phenothiazine scaffold of 1 could be only replaced with the Cl-
phenothiazine analogue or simplified into an indole moiety. The most active compound 12e, 
bearing a demethylated piperazine ring in addition to an indole heterocycle, showed an activity 
profile better than that of 1 and a cytotoxicity about 15-fold lower toward MRC-5 cells. 
 
4. MATERIAL AND METHODS 
4.1 Chemistry. Materials and Methods.  
1H NMR and 13C NMR spectra were recorded on JEOL Delta-270 or JEOL ECS-400 
spectrometers operating at the frequencies indicated. Chemical shift (δ) are in ppm, referenced 
to tetramethylsilane. Coupling constants (J) are reported in hertz and rounded to 0.5 Hz. 
Splitting patterns are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), 
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multiplet (m), broad (br) or some combination of them. Infrared spectra were obtained using a 
Durascope diamond ATR system. Mass spectra (HRMS) were recorded at the EPSRC National 
Mass Spectrometry Service Centre on a Thermo Scientific LTQ Orbitrap XL mass 
spectrometer using low-resolution ESI or high-resolution nano ESI techniques. The purity of 
the compounds was assessed by reverse-phase liquid chromatography coupled with a mass 
spectrometer (Agilent series 1100 LC/MSD) with a UV detector at k = 254 nm and an 
electrospray ionization source (ESI). HPLC analyses were performed at 0.4 mL/min flow rate 
and using a binary solvent system of 95:5 methyl alcohol/water. All the solvents were of HPLC 
grade. Mass spectra were acquired in positive mode scanning over the mass range of 50−1500. 
The following ion source parameters were used: drying gas flow, 9 mL/min; nebulize pressure, 
40 psig; and drying gas temperature, 350 °C. All target compounds possess a purity of ≥95%, 
as verified by HPLC analyses. TLC was performed using commercially available precoated 
plates and visualized with UV light at 254 nm; KMnO4 was used to reveal the products. Flash 
column chromatography was carried out using Fluorochem Davisil 40−63 μm, 60 Å. All 
reactions were conducted under a nitrogen atmosphere in oven-dried glassware unless stated 
otherwise. THF was distilled under nitrogen from sodium using a benzophenone indicator. 
Dichloromethane was purchased from Aldrich. All other solvents and commercially available 
reagents were used as received. 
 
4.1.1. Synthesis of 1-chloroethyl 2-(2-(2-(methylthio)-10H-phenothiazin-10-
yl)ethyl)piperidine-1-carboxylate (2) 
Thioridazine hydrochloride (1) (3.87 mmol, 1.57 g, 1 eq.) was dissolved in a round bottomed 
flask containing dry DCE (20 mL) and Et3N (7.74 mmol, 1 mL, 2 eq.). The mixture was stirred 
at r.t. for 20 minutes before that 1-chloroethyl chloroformate (7.74 mmol, 0.38 mL, 2 eq.) was 
added to the solution. The mixture was left under N2 atmosphere at reflux for 12h. Then, the 
reaction mixture was quenched with 10 mL of water and extracted twice with 20 mL of EtOAc. 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure giving a yellow-brown crude oil. The crude product was purified by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent.  
Yield: 84% (1.86 g). 1H NMR (400 MHz CDCl3) δ 7.13-7.01 (m, 2H), 7.01-6.90 (m, 1H), 
6.89-6.60 (m, 4H), 6.59-6.29 (m, 1H), 4.20-3.90 (m, 1H), 3.90-3.60 (m, 2H), 2.90-2.74 (m, 
1H), 2.74-2.57 (m, 1H), 2.36 (s, 3H), 2.25-2.04 (m, 1H), 1.77-1.60 (m, 3H), 1.58-1.16 (m, 7H) 
ppm. 13C NMR (100 MHz CDCl3) δ 152.9, 145.0, 137.9, 127.8, 127.7, 127.4, 122.8, 121.0, 
114.5, 83.4, 49.9, 44.5, 39.8, 29.1, 27.8, 25.4, 19.1, 16.5, 14.3 ppm. LRMS m/z (ES+) m/z: 
463 [M+H]+ 
 
4.1.2. Synthesis of 2-(methylthio)-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (3) 
Derivative 2 (3.84 mmol, 1.7 g, 1 eq.)  was dissolved in MeOH (20 mL) and the solution was 
stirred at reflux for 12h then the reaction mixture was concentrated by reduced pressure 
evaporation. Then, the reaction mixture was quenched with 20 ml of water and extracted twice 
with 20 mL of EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. The 
obtained product 3 was purified by chromatography on silica gel, using EtOAc/MeOH/Et3N 
(3.9:1:0.1) as eluent.  
Yield: 85% (1.1g). 1H NMR (400 MHz CDCl3) δ 9.25 (br. s., 1H), 7.20-7.08 (m, 2H), 7.03 (d, 
J = 6.9 Hz, 1H), 6.90 (d, J = 7.3 Hz, 2H), 6.82 (m, 2H), 4.13-3.93 (m, 2H), 3.29 (d, J = 12.8 
Hz, 1H), 3.02 (m, 1H), 2.68 (t, J = 12.1 Hz, 1H), 2.46 (s, 3H), 2.18-2.05 (m, 1H), 1.90-1.75 
(m, 3H), 1.75-1.53 (m, 3H), 1.44-1.28 (m, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 145.9, 
144.4, 138.3, 127.8, 127.7, 127.7, 125.9, 123.2, 122.5, 121.2, 116.3, 114.5, 55.7, 44.7, 43.7, 
30.7, 28.8, 22.5, 22.2, 16.4 ppm. LRMS m/z (ES+) m/z: 357 [M+H]+ 
 
4.1.3. General procedure for the synthesis of thioridazine derivatives (4a-c) 
The 2-(methylthio)-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine 3 (0.14 mmol, 50 mg, 1 
eq.) was added to a round bottomed flask containing a solution of the appropriate 
aldehyde/ketone (0.21 mmol, 1.5 eq.) in THF (5 mL). The solution was then allowed to stir at 
room temperature for 30 minutes. Then, NaBH(AcO)3 (0.28 mmol, 60 mg, 2 eq.) was added 
and the reaction was allowed to react for 24h at r.t.. The reaction was quenched with (20mL) 
NaOH 1N solution and the resulting mixture was allowed to stir for 20 minutes. Then the 
organic solvent was removed under reduced pressure evaporation. The residue was added with 
EtOAc and extracted (3 x 10 mL) and finally dried over anhydrous MgSO4. The crude products 
4a-c were purified by chromatography on silica gel, using EtOAc/MeOH/Et3N (3.9:1:0.1) as 
eluent.  
4.1.3.1. 10-(2-(1-Benzylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine (4a): Yield: 
67% (42 mg). 1H NMR (400 MHz CDCl3) δ 7.28-7.17 (m, 5H) 7.14-7.10 (m, 2H), 7.03 (d, J 
= 4.0 Hz, 1H), 6.92-6.84 (m, 2H), 6.81 (d, J = 4.0 Hz, 2H), 3.97-3.83 (m, 3H), 3.32 (d, J = 8.0 
Hz, 1H), 2.75-2.70 (m, 1H), 2.60-2.55 (m, 1H), 2.43 (s, 3H), 2.14 (s, 2H), 2.00-1.94 (m, 1H), 
1.77-1.41 (m, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 146.0, 145.1, 139.7, 137.6, 129.1, 
128.8, 128.6, 128.3, 127.6, 127.6, 127.3, 126.8 125.4, 122.6, 122.3, 120.9, 115.8, 114.7, 58.4, 
57.7, 55.7, 50.6, 44.2, 29.6, 24.4, 23.1, 16.6 ppm. LRMS m/z (ES+) m/z: 447 [M+H]+. HRMS 
(ESI) m/z calcd. For C27H31N2S2 [M +H] 447.1923, found 447.1913. 
4.1.3.2. 2-(Methylthio)-10-(2-(1-propylpiperidin-2-yl)ethyl)-10H-phenothiazine (4b): Yield: 
62% (34.5 mg). 1H NMR (400 MHz CDCl3) δ 7.15-7.11 (m, 2H), 7.03 (d, J = 4.0 Hz, 1H), 
6.92-6.88 (m, 2H), 6.80 (d, J = 4.0 Hz, 2H), 3.94-3.99 (m, 1H), 3.83-3.79 (m, 1H), 2.82-2.77 
(m, 1H), 2.51-2.48 (m, 2H), 2.45 (s, 3H), 2.33-2.22 (m, 2H), 2.16-2.06 (m, 1H), 1.85-1.56 (m, 
4H), 1.43-1.29 (m, 5H), 0.75 (t, J = 8.0 Hz, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 145.8, 
145.0, 137.6, 127.6, 127.5, 127.3, 125.4, 122.6, 122.3, 120.9, 115.8, 114.7, 57.9, 55.7, 51.4, 
44.4, 30.2, 27.9, 25.2, 23.3, 18.9, 16.6, 12.0 ppm. LRMS m/z (ES+) m/z: 399 [M+H]+. HRMS 
(ESI) m/z calcd. for C23H31N2S2 [M +H] 399.1923, found 399.1916. 
4.1.3.3 10-(2-(1-isopropylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine (4c): Yield: 
68% (38 mg). 1H NMR (400 MHz CDCl3) δ 7.15-7.11 (m, 2H), 7.03 (d, J = 4.0 Hz, 1H), 6.92-
6.88 (m, 2H), 6.80 (d, J = 4.0 Hz, 2H), 3.96-3.98 (m, 1H), 3.83-3.79 (m, 1H), 3.15 (t, J = 8.0 
Hz, 1H), 2.81-2.75 (m, 1H), 2.62-2.59 (m, 1H), 2.44 (s, 3H), 2.20-2.03 (m, 2H), 1.85-1.24 (m, 
7H), 1.05 (d, J = 8.0 Hz, 3H), 0.77 (d, J = 8.0 Hz, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 
145.8, 127.6, 127.5, 127.3, 122.6, 120.9, 115.7, 114.7, 56.1, 44.1, 43.9, 31.0, 28.5, 26.0, 24.0, 
21.8, 16.6, 13.9 ppm. LRMS m/z (ES+) m/z: 399 [M+H]+. HRMS (ESI) m/z calcd. for 
C23H31N2S2 [M +H] 399.1923, found 399.1916. 
 
4.1.4. General procedure for the synthesis of compound (6a-c) 
The appropriate 2-substituted phenothiazine 5a-c (0.42 mmol, 1eq.) was added to 5 mL of 
DMF in a double neck round bottomed flask. NaH (0.46 mmol, 11 mg, 1.1 eq.) was added to 
the stirring solution at 0°C, and the mixture was allowed to reach r.t stirring for 20 minutes. 
Then, 1-bromo-3-chloropropane (0.46 mmol, 45 L 1.1eq) was added to the stirring solution. 
The reaction mixture was allowed to stir under N2 atmosphere for 12h at r.t. before being 
quenched with 10 mL of water and extracted twice with 20 mL of EtOAc. The combined 
organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated under 
reduced pressure giving a yellow-brown crude oil. The obtained product was purified by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent.  
4.1.4.1. 10-(3-Chloropropyl)-2-(methylthio)-10H-phenothiazine (6a): Yield: 93% (125 mg). 
1H NMR (400 MHz CDCl3) δ 7.18-7.14 (m, 2H), 7.06 (d, J = 8.0 Hz, 1H), 6.95-6.88 (m, 2H), 
6.84-6.81 (m, 2H), 4.06 (t, J = 8.0 Hz, 2H), 3.65 (t, J = 8.0 Hz, 2H), 2.46 (s, 3H), 2.22 (t, J = 
8.0 Hz, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.6, 145.9, 137.8, 127.8, 127.7, 127.5, 
125.8, 123.0, 122.7, 121.1, 115.9, 114.6, 44.1, 42.5, 29.7, 16.5 ppm. LRMS m/z (ES+) m/z: 
322 [M+H]+. 
4.1.4.2. 2-Chloro-10-(3-chloropropyl)-10H-phenothiazine (6b): Yield: 84% (109 mg). 1H 
NMR (400 MHz CDCl3) δ 7.19-7.14 (m, 2H) 7.04 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 8.0 Hz, 1H), 
6.91-6.88 (m, 2H), 6.86 (s, 1H), 4.04 (t, J = 8.0 Hz, 2H), 3.65 (t, J = 8.0 Hz, 2H), 2.25-2.18 (m, 
2H) ppm. 13C NMR (100 MHz CDCl3) δ 146.5, 144.4, 133.4, 128.2, 127.8, 127.6, 125.5, 124.2, 
123.3, 122.7, 116.0, 115.9, 44.1, 42.3, 29.5 ppm. LRMS m/z (ES+) m/z: 332 [M+Na]+ 
4.1.4.3. 10-(3-Chloropropyl)-10H-phenothiazine (6c): Yield: 82% (94 mg). 1H NMR (400 
MHz CDCl3) δ 7.19-7.15 (m, 4H), 6.96-6.89 (m, 4H), 4.07 (t, J = 8.0 Hz, 2H), 3.66 (t, J = 8.0 
Hz, 2H), 2.23 (t, J = 8.0 Hz, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.2, 127.8, 127.4, 
125.8, 122.9, 115.7, 44.0, 42.6, 29.7 ppm. LRMS m/z (ES+) m/z: 276 [M+H]+ 
 
4.1.5. General procedure for the synthesis of thioridazine derivatives (7a-i) 
The appropriate chloro-derivative 6a-c (0.18 mmol, 1 eq.) was dissolved in a round bottomed 
flask containing dry DMF (10 mL) and Et(iPr)2N (DIPEA, 0.19 mmol, 1.1 eq.). The appropriate 
amine (N-substituted piperazine or thiomorpholine) (0.72 mmol, 4 eq.) was then added to the 
solution followed by NaI (0.036 mmol, 5 mg, 0.2 eq.). The mixture was left under N2 
atmosphere at 150 °C for 3 h, after which time it was added with water (10 mL) and extracted 
twice with EtOAc (20 mL). The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure. The obtained product was purified by 
chromatography on silica gel, using EtOAc/MeOH/Et3N (3.9:1:0.1) as eluent. 
4.1.5.1. 10-(3-(4-Methylpiperazin-1-yl)propyl)-10H-phenothiazine (7a):[28] Yield: 99% (60 
mg). 1H NMR (400 MHz CDCl3) δ 7.12 (t, J = 8.0 Hz, 4H), 6.90 (t, J = 8.0 Hz, 4H), 3.90 (t, J 
= 8.0 Hz, 2H), 2.46 (t, J = 8.0 Hz, 2H), 2.42-2.34 (m, 8H), 2.26 (s, 3H), 1.94 (d, J = 8.0 Hz, 
2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.2, 127.5, 127.3, 125.1, 122.5, 115.6, 55.7, 55.1, 
53.2, 46.0, 45.4, 24.5 ppm. LRMS m/z (ES+) m/z: 340 [M+H]+.  
4.1.5.2. 10-(3-(4-Phenylpiperazin-1-yl)propyl)-10H-phenothiazine (7b): Yield: 62% (44 mg). 
1H NMR (400 MHz CDCl3) δ 7.25 (t, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 4H), 6.92-6.88 (m, 
6H), 6.84 (t, J = 8.0 Hz, 1H), 3.95 (t, J = 8.0 Hz, 2H), 3.14 (t, J = 8.0 Hz, 4H), 2.57 (t, J = 8.0 
Hz, 4H), 2.53 (t, J = 8.0 Hz, 2H), 2.02-1.95 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 151.4, 
145.3, 129.2, 127.5, 127.3, 125.2, 122.5, 119.7, 116.1, 115.6, 55.7, 53.4, 49.2, 45.3, 24.4 ppm. 
LRMS m/z (ES+) m/z: 402 [M+H]+. HRMS (ESI) m/z calcd. for C25H28N3S [M +H] 402.1998, 
found 402.1995. 
4.1.5.3. 10-(3-(4-Methylpiperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine (7c): Yield: 
99% (68 mg). 1H NMR (400 MHz CDCl3) δ 7.11-7.09 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.90-
6.85 (m, 2H), 6.80-6.77 (m, 2H), 3.89 (t, J = 8.0 Hz, 2H), 2.50-2.33 (m, 8H), 2.46 (t, J = 8.0 
Hz, 2H), 2.44 (s, 3H), 2.26 (s, 3H), 1.94-1.92 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 
145.2, 144.9, 137.5, 127.6, 127.5, 127.3, 125.2, 122.6, 122.2, 120.8, 115.8, 114.7, 55.6, 55.1, 
53.2, 46.0, 45.3, 24.4, 16.6 ppm. LRMS m/z (ES+) m/z: 386 [M+H]+. HRMS (ESI) m/z calcd. 
for C21H28N3S2 [M +H] 386.1719, found 386.1739. 
4.1.5.4. 2-(Methylthio)-10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine (7d): 
Yield: 77% (62 mg). 1H NMR (400 MHz CDCl3) δ 7.24 (t, J = 8.0 Hz, 2H), 7.12 (d, J = 8.0 
Hz, 2H), 7.03 (d, J = 8.0 Hz, 1H), 6.92-6.88 (m, 4H), 6.85-6.80 (m, 3H), 3.94 (t, J = 8.0 Hz, 
2H), 3.14 (t, J = 8.0 Hz, 4H), 2.56 (t, J = 8.0 Hz, 4H), 2.51 (t, J = 8.0 Hz, 2H), 2.45 (s, 3H), 
1.99-1.96 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 151.4, 145.7, 145.02, 137.6, 129.2, 
127.6, 127.5, 127.3, 125.3, 122.7, 122.3, 120.9, 119.7, 116.1, 115.8, 114.8, 55.7, 53.4, 49.2, 
45.3, 24.4, 16.6 ppm. LRMS m/z (ES+) m/z: 448 [M+H]+. HRMS (ESI) m/z calcd. for 
C26H30N3S2 [M +H] 448.1876, found 448.1866. 
4.1.5.5. 2-(Methylthio)-10-(3-thiomorpholinopropyl)-10H-phenothiazine (7e): Yield: 99% (69 
mg). 1H NMR (400 MHz CDCl3) δ 7.14-7.03 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.91-6.86 (m, 
2H), 6.80-6.77 (m, 2H), 3.90 (t, J = 8.0 Hz, 2H), 2.63-2.57 (m, 8H), 2.45 (s, 3H), 1.89 (t, J = 
8.0 Hz, 2H) 1.34-1.22 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.7, 144.9, 137.6, 127.6, 
127.5, 127.3, 122.6, 122.2, 120.8, 115.9, 114.8, 56.1, 55.2, 45.1, 28.1, 24.1, 16.6 ppm. LRMS 
m/z (ES+) m/z: 389 [M+H]+. HRMS (ESI) m/z calcd. for C20H25N2S3 [M +H] 389.1174, found 
389.1172. 
4.1.5.6. 10-(3-(4-Adamantan-1-yl)piperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine 
(7f): Yield: 71% (64 mg). 1H NMR (400 MHz CDCl3) δ 7.17-7.07 (m, 2H), 7.02 (d, J = 7.8 
Hz, 1H), 6.92-6.85 (m, 2H), 6.84-6.76 (m, 2H), 3.89 (t, J = 6.9 Hz, 2H), 2.56-2.26 (m, 12H), 
2.07-1.88 (m, 8H), 1.88-1.74 (m, 4H), 1.71-1.53 (m, 4H), 1.35 (d, J = 11.9 Hz, 2H) ppm. 13C 
NMR (100 MHz CDCl3) δ 145.8, 144.9, 137.6, 127.6, 127.5, 127.3, 125.3, 122.7, 122.3, 120.8, 
115.9, 114.7, 55.4, 54.3, 53.2, 46.7, 45.4, 45.2, 44.0, 43.9, 41.0, 38.7, 38.0, 36.8, 36.7, 29.7, 
24.3, 16.6 ppm. LRMS m/z (ES+) m/z: 506 [M+H]+. HRMS (ESI) m/z calcd. for C30H40N3S2 
[M +H] 506.2658, found 506.2644. 
4.1.5.7. 10-(3-(4-(Adamantan-2-yl)piperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine 
(7g): Yield: 72% (65 mg). 1H NMR (400 MHz CDCl3) δ 7.15-7.04 (m, 2H), 7.01 (d, J = 7.8 
Hz, 1H), 6.92-6.81 (m, 2H), 6.81 - 6.73 (m, 2H), 3.87 (t, J = 6.6 Hz, 2H), 3.58-3.41 (m, 1H), 
3.38-3.25 (m, 1H), 2.70 (s, 3H), 2.64-2.59 (m, 2H), 2.59-2.55 (m, 2H), 2.55-2.49 (m, 2H), 2.49-
2.44 (m, 3H), 2.43 (s, 3H), 2.07 (m, 5H), 1.97-1.87 (m, 2H), 1.73 (m, 5H), 1.64 (d, J = 2.3 Hz, 
3H) ppm. 13C NMR (100 MHz CDCl3) δ 145.8, 144.9, 137.6, 127.6, 127.5, 127.3, 125.2, 122.6, 
122.2, 120.8, 115.8, 114.7, 67.8, 56.0, 54.0, 49.6, 45.6, 40.6, 37.9, 37.3, 31.4, 29.1, 28.9, 27.6, 
27.4, 24.4, 16.6 ppm. LRMS m/z (ES+) m/z: 506 [M+H]+. HRMS (ESI) m/z calcd. for 
C30H40N3S2 [M +H] 506.2658, found 506.2648. 
4.1.5.8. 2-Chloro-10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine (7h): Yield: 57% 
(44 mg). 1H NMR (400 MHz CDCl3) δ 7.24 (t, J = 8.0 Hz, 2H), 7.17-7.11 (m, 2H), 7.01 (d, J 
= 8.0 Hz, 1H), 6.94-6.63 (m, 7H), 3.92 (t, J = 8.0 Hz, 2H), 3.15 (t, J = 8.0 Hz, 4H), 2.57 (t, J = 
8.0 Hz, 4H), 2.51 (t, J = 8.0 Hz, 2H), 2.00-1.96 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 
151.4, 146.6, 144.6, 133.3, 129.2, 128.0, 127.6, 127.5, 124.8, 123.6, 123.0, 122.3, 119.8, 116.1, 
115.9, 55.6, 53.5, 49.2, 45.4, 24.3 ppm. LRMS m/z (ES+) m/z: 436 [M+H]+. HRMS (ESI) 
m/z calcd. for C25H27ClN3S [M +H] 436.1609, found 436.1618. 
4.1.5.9. 2-Chloro-10-(3-thiomorpholinopropyl)-10H-phenothiazine (7i): Yield: 90% (61 mg). 
1H NMR (400 MHz CDCl3) δ 7.15-7.08 (m, 2H), 6.99 (d, J = 8.0 Hz, 1H), 6.93-6.81 (m, 4H), 
3.88 (t, J = 8.0 Hz, 2H), 2.66-2.57 (m, 8H), 2.45 (t, J =8.0 Hz, 2H), 1.91-1.85 (m, 2H) ppm. 
13C NMR (100 MHz CDCl3) δ 146.5, 144.6, 133.2, 127.9, 127.6, 127.5, 124.8, 123.5, 122.9, 
122.3, 115.9, 56.0, 55.8, 45.1, 28.1, 24.0 ppm. LRMS m/z (ES+) m/z: 377 [M+H]+. HRMS 
(ESI) m/z calcd. for C19H22ClN2S2 [M +H] 377.0907, found 377.0917. 
 
4.1.6. 2-Chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethanone (8) 
The phenothiazine 5a (1.22 mmol, 300 mg, 1 eq.) was dissolved to 15 mL of DMF in a double 
neck round bottomed flask. NaH (1.83 mmol, 44 mg, 1.5 eq.) was added to the stirring solution 
at 0°C, which then was allowed to reach r.t. under stirring for 20 minutes. Then, 2-chloroacetyl 
chloride (3.66 mmol, 0.29 mL, 3 eq.) was added and the reaction mixture was stirred under N2 
atmosphere for 3h at r.t.. The reaction mixture was then quenched with water (10 mL) and 
extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. 
The obtained product was purified by chromatography on silica gel, using hexane/EtOAc (3:2) 
as eluent.  
Yield: 58% (227 mg). 1H NMR (400 MHz CDCl3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.47-7.43 (m, 
2H), 7.36-7.31 (m, 2H), 7.27-7.23 (m, 1H), 7.14-7.11 (m, 1H), 4.16 (d, J = 8.0 Hz, 2H), 2.49 
(s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 166.3, 138.8, 138.3, 137.5, 128.3, 128.2, 127.7, 
127.5, 126.5, 125.7, 124.1, 40.7, 15.9 ppm. LRMS m/z (ES+) m/z: 322 [M+H]+.  
 
4.1.7. Synthesis of 2-(4-methylpiperazin-1-yl)-1-(2-(methylthio)-10H-phenothiazin-10-
yl)ethanone (9a) 
The 1-methylpiperazine (0.63 mmol, 0.07 mL, 4 eq.) was dissolved in a round bottomed flask 
containing dry DMF (5 mL) and Et(iPr)2N (DIPEA, 0.17 mmol, 1.1 eq.). The mixture was 
stirred at r.t for 20 minutes and then 2-chloro-1-(2-(methylthio)-10H-phenothiazin-10-
yl)ethanone (8) (0.15 mmol, 48 mg, 1 eq.) was added to the solution followed by NaI (0.03 
mmol, 4.5 mg, 0.2 eq.). The mixture was left under N2 atmosphere at 153 °C for 3 h. Then, the 
reaction mixture was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure giving a yellow-brown crude oil. The obtained product was purified by 
chromatography on silica gel, using EtOAc/MeOH/Et3N (3.9:1:0.1) as eluent.  
Yield: 96% (55 mg). 1H NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.41 (d, J = 8.0 Hz, 
1H), 7.32-7.26 (m, 2H), 7.22-7.18 (m, 1H), 7.10-7.08 (m, 1H), 3.30-3.31 (m, 2H), 2.47 (s, 3H), 
2.44-2.27 (8H), 2.22 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 168.6, 139.3, 138.6, 137.9, 
128.0, 127.9, 127.0, 126.9, 125.1, 124.9, 60.4, 54.9, 52.9, 45.9, 16.2 ppm. LRMS m/z (ES+) 
m/z: 386 [M+H]+. HRMS (ESI) m/z calcd.  for C20H24N3S2O [M +H], 386.1355 found 
386.1351. 
 
4.1.8. Synthesis of 1-(2-(methylthio)-10H-phenothiazin-10-yl)-2-(piperidin-1-yl)ethanone (9b) 
Piperidine (1.22 mmol, 0.12 mL, 4 eq.) was added to a round bottomed flask containing DMF 
(5 mL) and Et(iPr)2N (DIPEA, 0.31 mmol, 1 eq.) and the mixture was allowed to stir at room 
temperature for 30 minutes before 2-chloro-1-(2-(methylthio)-10H-phenothiazin-10-
yl)ethanone (8) (0.31 mmol, 98 mg, 1 eq.) was added to the solution. The reaction was allowed 
to stir for 3h at 150 °C. The reaction mixture was then quenched with water (10 mL) and 
extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. 
The obtained product was purified by chromatography on silica gel, using EtOAc/MeOH/Et3N 
(3.9:1:0.1) as eluent.  
Yield: 91% (104 mg). 1H NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.40 (d, J = 8.0 Hz, 
1H), 7.30-7.24 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 12.0 Hz, 2H), 3.24-3.23 (d, J = 
8.0 Hz, 2H), 2.47 (s, 3H), 2.35 (m, 4H), 1.46-1.41 (m, 4H), 1.32-1.29 (m, 2H) ppm. 13C NMR 
(100 MHz CDCl3) δ 163.7, 138.9, 135.8, 135.7, 132.3, 132.2, 126.7, 126.7, 122.2, 118.0, 116.2, 
56.8, 56.1, 25.2, 24.2, 16.0 ppm. LRMS m/z (ES+) m/z: 371 [M+H]+  
 
4.1.9. Synthesis of t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate (11)  
The 2-(piperidin-2-yl)ethanol 10 (1.55 mmol, 200 mg, 1 eq.) was added to 10 mL mixture (1:1) 
of CH2Cl2 and Na2CO3 aqueous solution (10 mL total) in a round bottomed flask. Di-t-butyl 
dicarbonate (1.70 mmol, 371 mg, 1.1 eq.) was added to the stirring solution. The reaction 
mixture was stirred for 24h at room temperature. Then, the reaction mixture was diluted with 
10 mL of water and extracted once with 10 mL of CH2Cl2 and twice with 20 mL of EtOAc. 
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure giving a yellow crude oil. The crude product was purified by 
chromatography on silica gel, using hexane/EtOAc (3:2) as eluent affording the N-Boc-
protected amino alcohol. Yield: 98% (314 mg). 1H NMR (400 MHz CDCl3) δ 4.35-4.19 (m, 
1H) 3.85-3.80 (m, 2H), 3.48-3.42 (m, 1H), 3.27 (br s, 1H), 2.59-2.52 (m, 1H), 1.81 (t, J = 12.0 
Hz, 1H), 1.64-1.54 (m, 1H), 1.51-1.37 (m, 5H), 1.37 (s, 9H), 1.29-1.25 (m, 1H) ppm. 13C NMR 
(100 MHz CDCl3) δ 155.0, 80.2, 58.7, 46.1, 39.4, 32.5, 28.5, 28.4, 25.6, 19.0 ppm. LRMS m/z 
(ES+) m/z: 230 [M+Na]+  
To a solution of the above synthesised N-Boc-amino alcohol (0.43 mmol, 89 mg, 1eq.) in 
CH2Cl2 (10 mL) was added PPh3 (0.47 mmol, 123 mg, 1.1 eq.) followed by a solution of CBr4 
(0.47 mmol, 156 mg, 1.1 eq.) in 20 mL of CH2Cl2 at r.t. and the mixture was allowed to stir for 
45 min. Then, the reaction mixture was concentrated under reduced pressure giving a yellow 
crude oil. The obtained product was then immediately purified by chromatography on silica 
gel, using hexane/EtOAc (9:1) as eluent. The pure product 11 was obtained as a yellow oil. 
Yield: 79% (99 mg). 1H NMR (400 MHz CDCl3) δ 4.35-4.31 (m, 1H) 4.02-3.84 (m, 1H), 3.33-
3.19 (m, 2H), 2.70-2.64 (t, J = 12.0 Hz, 1H), 2.33-2.23 (m, 1H), 1.90-1.64 (m, 1H), 1.63-1.43 
(m, 5H), 1.40 (s, 9H), 1.38-1.31 (m, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 155.2, 79.6, 49.5, 
38.7, 33.6, 30.3, 28.7, 28.5, 25.5, 19.2 ppm. LRMS m/z (ES+) m/z: 293 [M+H]+ 
4.1.10. General procedure for the synthesis of Boc-protected thioridazine derivatives (S12a-e) 
The appropriate 2-substituted phenothiazine (5a-c) or carbazole, indole, or benzimidazole 
(0.42 mmol, 1eq.) was added to 10 mL of DMF in a double neck round bottomed flask. NaH 
(0.52 mmol, 12.5 mg, 1.2 eq.) was added to the stirring solution at 0°C, which then was allowed 
to reach r.t stirring for 20 minutes. Then, t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate 
(11) (0.52 mmol, 152 mg, 1.2eq.) and NaI (0.02 mmol, 3 mg, 0.1eq) were added to the stirring
solution. The reaction mixture was allowed to stir under N2 atmosphere for 12h at r.t. Then, the
reaction mixture was quenched with 20 mL of water and extracted twice with 20 mL of EtOAc.
The combined organic layers were washed with brine, dried over Na2SO4 and concentrated
under reduced pressure giving a yellow-brown crude oil. The crude product was purified by
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent.
4.1.10.1. t-Butyl 2-(2-(10H-phenothiazin-10-yl)ethyl)piperidine-1-carboxylate (S12a): Yield: 
45% (77 mg). 1H NMR (400 MHz CDCl3) δ 7.16-7.12 (m, 4H), 6.93-6.89 (m, 2H), 6.84 (d, J 
= 8.0 Hz, 2H), 4.45-4.35 (m, 1H), 4.08-3.96 (m, 1H), 3.92-3.74 (m, 2H), 3.38-3.28 (m, 1H), 
2.83-2.69 (m, 1H), 2.37-2.18 (m, 1H), 1.91-1.85 (m, 1H), 1.67-1.49 (m, 5H), 1.40 (s, 9H) ppm. 
13C NMR (100 MHz CDCl3) δ 155.1, 145.3, 127.6, 127.3, 125.1, 122.5, 115.3, 79.4, 49.5, 38.7, 
33.6, 30.3, 28.7, 28.5, 25.5, 19.2 ppm. LRMS m/z (ES+) m/z: 411 [M+H]+ 
4.1.10.2. t-Butyl 2-(2-(2-chloro-10H-phenothiazin-10-yl)ethyl)piperidine-1-carboxylate 
(S12b): Yield: 61% (111 mg). 1H NMR (400 MHz CDCl3) δ 7.17-7.11 (m, 2H) 7.02 (d, J = 
8.0 Hz, 1H), 6.95-6.83 (m, 3H), 6.78 (d, J = 4.0 Hz, 1H), 4.44-4.39 (m, 1H), 4.38-4.35 (m, 1H), 
4.05-4.00 (m, 1H), 3.88-3.79 (m, 2H), 2.78 (t, J = 12 Hz, 1H), 2.22-2.16 (m, 1H), 1.90-1.81 
(m, 1H), 1.68-1.45 (m, 5H), 1.42 (s, 9H) ppm. 13C NMR (100 MHz CDCl3) δ 155.2, 146.7, 
144.6, 133.4, 128.1, 127.5, 124.9, 123.0, 122.4, 115.7, 79.6, 48.8, 44.8, 39.1, 29.3, 28.5, 27.7, 
25.6, 19.3 ppm. LRMS m/z (ES+) m/z: 468 [M+Na]+  
4.1.10.3. t-Butyl 2-(2-(9H-carbazol-9-yl)ethyl)piperidine-1-carboxylate (S12c): Yield: 61% 
(94 mg). 1H NMR (400 MHz CD3OD) δ 8.37 (d, J = 7.8 Hz, 2H), 7.87-7.64 (m, 4H), 7.60-
7.35 (m, 2H), 4.74 (m, 1H), 4.69-4.59 (m, 1H), 4.36-4.18 (m, 1H), 3.69-3.60 (m, 2H), 3.10-
3.07 (m, 1H), 2.73-2.53 (m, 1H), 2.22 (m, 1H), 2.00-1.86 (m, 5H), 1.85-1.76 (m, 9H) ppm. 13C 
NMR (100 MHz CD3OD) δ 155.8, 140.6, 140.5, 125.9, 125.6, 123.4, 123.3, 120.4, 120.0, 
119.1, 118.7, 110.8, 108.7, 80.1, 78.6, 40.2, 33.2, 28.5, 27.9, 27.8, 25.7, 19.1, 19.0 ppm. LRMS 
m/z (ES+) m/z: 401 [M+Na]+ 
4.1.10.4. t-Butyl 2-(2-(1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate (S12d): 
Yield: 63% (87 mg). 1H NMR (400 MHz CDCl3) δ 7.91 (s, 1H), 7.84-7.67 (m, 1H), 7.39-7.31 
(m, 1H), 7.31-7.09 (m, 2H), 4.49-4.19 (m, 1H), 4.10-3.90 (m, 2H), 2.81-2.65 (m, 1H), 2.38-
2.18 (m, 1H), 1.96-1.77 (m, 1H), 1.72-1.44 (m, 7H), 1.44-1.29 (m, 9H) ppm. 13C NMR (100 
MHz CDCl3) δ 155.2, 144.0, 143.2, 133.7, 122.9, 122.1, 120.6, 109.5, 79.9, 60.4, 42.4, 30.1, 
28.9, 28.5, 25.5, 19.2, 14.2 ppm. LRMS m/z (ES+) m/z: 330 [M+H]+ 
4.1.10.5 t-Butyl 2-(2-(1H-indol-1-yl)ethyl)piperidine-1-carboxylate (S12e): Yield: 42% (58 
mg). 1H NMR (400 MHz CDCl3) δ 7.62 (d, J = 8.0 Hz, 1H) 7.31 (d, J = 8.0 Hz, 1H), 7.22-7.18 
(m, 1H), 7.12-7.07 (m, 2H), 6.48 (d, J = 4.0 Hz, 1H), 4.38-4.33 (m, 1H), 4.15-4.03 (m, 3H), 
2.81 (t, J = 8.0 Hz, 1H), 2.31-2.21 (m, 1H), 1.93-1.86 (m, 1H), 1.68-1.58 (m, 6H), 1.45 (s, 9H) 
ppm 13C NMR (100 MHz CDCl3) δ 155.2, 135.8, 128.8, 127.9, 121.5, 121.1, 119.4, 109.2, 
101.2, 79.7, 43.8, 30.7, 29.0, 28.6, 25.6, 19.2 ppm. LRMS m/z (ES+) m/z: 352 [M+Na]+ 
 
4.1.11. General procedure for the synthesis of thioridazine derivatives (12a-e) 
The appropriate Boc-protected compound (S12a-e) (0.24 mmol, 1 eq.) was added to a round 
bottom flask containing 5 ml HCl saturated solution in EtOAc. The reaction mixture was 
allowed to stir at room temperature for 24h. The solvent was removed under reduced pressure 
giving a white solid as product of the reaction. The solid products 12a-e were washed several 
times with cold Et2O. 
4.1.11.1. 10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (12a): Yield: 99% (73 mg). 1H 
NMR (400 MHz CDCl3) δ  9.41 (br. s., 1H), 9.24 (br. s., 1H), 7.15-7.12 (m, 4H), 6.92-6.86 (m, 
4H), 3.97-3.92 (m, 2H), 3.49-3.45 (m, 1H), 3.08-3.05 (m, 1H), 2.73-2.57 (m, 1H), 2.45-2.43 
(m, 1H), 2.18-2.06 (m, 1H), 1.93-1.74 (m, 3H), 1.69-1.60 (m, 2H), 1.44-1.34 (m, 1H) ppm. 13C 
NMR (100 MHz CDCl3) δ 145.3, 127.7, 127.4, 125.4, 122.7, 115.6, 55.6, 46.8, 44.3, 33.7, 
32.4, 25.9, 24.5 ppm. LRMS m/z (ES+) m/z: 311 [M+H]+. HRMS (ESI) m/z calcd. for 
C19H22N2S [M +H] 311.1576, found 311.1579. 
4.1.11.2. Synthesis of 2-chloro-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (12b): Yield: 
94% (77 mg). 1H NMR (400 MHz CDCl3) δ 9.54 (br s, 1H), 9.34 (br s, 1H), 7.19 (t, J = 8.0Hz 
1H), 7.13 (d, J = 8.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.95-6.89 (m, 4H), 4.07-3.96 (m, 2H), 
3.31 (d, J = 8.0 Hz, 1H), 3.12-3.04 (m, 1H), 2.77-2.68 (m, 1H), 2.50-2.42 (m, 1H), 2.13-2.09 
(m, 1H), 1.85-1.69 (m, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 146.6, 144.5, 133.3, 128.0, 
127.6, 127.5, 125.1, 123.9, 123.1, 122.5, 115.9, 55.4, 46.7, 44.4, 33.5, 29.7, 25.8, 24.4 ppm. 
LRMS m/z (ES+) m/z: 345 [M+H]+. HRMS (ESI) m/z calcd. for C19H21ClN2S [M +H] 
345.1187, found 345.1194. 
4.1.11.3. Synthesis of 9-(2-(piperidin-2-yl)ethyl)-9H-carbazole (12c): Yield: 95% (63 mg). 1H 
NMR (400 MHz CDCl3) δ 9.66 (br s, 1H), 9.41 (br s, 1H), 8.02 (d, J = 8.0, 2H), 7.46-7.37 (m, 
4H), 7.17 (t, J = 8.0, 2H), 4.51-4.43 (m, 1H), 4.31-4.25 (m, 1H), 3.38-3.36 (m, 1H), 3.02-2.90 
(m, 1H), 2.70-2.67 (m, 1H), 2.49-2.48 (m, 1H), 2.18-2.12 (m, 1H), 1.88-1.61 (m, 6H) ppm. 13C 
NMR (100 MHz CDCl3) δ 140.0, 126.1, 122.9, 120.4, 119.3, 108.8, 55.5, 44.9, 39.5, 32.7, 
30.0, 22.3, 22.0 ppm. LRMS m/z (ES+) m/z: 279 [M+H]+. HRMS (ESI) m/z calcd. for 
C19H22N2 [M +H] 279.1856, found 279.1855. 
4.1.11.4. Synthesis of 1-(2-(piperidin-2-yl)ethyl)-1H-benzo[d]imidazole (12d): Yield: 90% (49 
mg). 1H NMR (400 MHz CDCl3) δ 10.17 (s 1H), 9.68 (br s, 2H), 7.82 (t, J = 8.0 Hz, 2H), 7.44-
7.36 (m, 2H), 5.01-4.79 (m, 2H), 3.46-3.43 (m, 1H), 3.36-3.25 (m, 1H), 2.98-2.94 (m, 1H), 
2.85-2.71 (m, 1H), 2.50-2.36 (m, 1H) 1.90-1.75 (m, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 
140.9, 130.7, 126.9, 126.7, 115.6, 112.7, 54.1, 45.0, 43.7, 33.4, 28.7, 22.3, 20.9 ppm. LRMS 
m/z (ES+) m/z: 230 [M+H]+. HRMS (ESI) m/z calcd. for C14H19N3 [M +H] 230.1652, found 
230.1652. 
4.1.11.5 1-(2-(piperidin-2-yl)ethyl)-1H-indole (12e): Yield: 94% (51 mg). 1H NMR (400 MHz 
CD3OD) δ 7.42-7.34 (m, 1H), 7.24-7.19 (m, 1H), 7.10-7.01 (m, 2H), 6.90-6.80 (m, 2H), 4.12-
4.01 (m, 2H), 3.39-3.24 (m, 1H), 2.95-2.89 (m, 2H), 2.82-2.73 (m, 1H), 2.75-2.59 (m, 1H), 
2.49-2.40 (m, 1H), 2.38-2.29 (m, 2H), 1.84-1.67 (m, 3H) ppm. 13C NMR (100 MHz (CD3)2SO) 
δ 135.8, 127.9, 121.8, 121.1, 119.6, 119.1, 109.7, 54.2, 45.2, 43.6, 33.3, 28.8, 22.1, 20.8 ppm. 
LRMS m/z (ES+) m/z: 229 [M+H]+. HRMS (ESI) m/z calcd. for C15H20N2 [M +H] 229.1626, 
found 229.1701. 
 
4.1.12. General procedure for the synthesis of thioridazine derivatives (13a-d) 
Compounds (12a-d) (0.14 mmol, 1 eq.) were added to a round bottom flask containing THF (5 
mL) and formaldehyde aqueous solution 37% w/v (0.28 mmol, 2 eq.). The solution was then 
allowed to stir at room temperature for 30 minutes. Then, NaBH(AcO)3 (0.28 mmol, 59 mg, 
2.0 eq.) was added. The reaction was then stirred for 24h at r.t. after which time the solution 
was quenched with (20mL) NaOH 1N aqueous solution. The resulting mixture was stirred for 
further 20 minutes and then the organic solvent was removed through reduced pressure 
evaporation. The residue was diluted with EtOAc, extracted twice with EtOAc (10 mL) and 
dried over anhydrous MgSO4. The solvent was concentrated under reduced pressure and the 
obtained product was purified by chromatography on silica gel, using EtOAc/MeOH/Et3N 
(3.9:1:0.1) as eluent.  
4.1.12.1. 10-(2-(1-Methylpiperidin-2-yl)ethyl)-10H-phenothiazine (13a): Yield: 47% (21.3 
mg). 1H NMR (400 MHz CDCl3) δ 7.19-7.07 (m, 4H), 6.95-6.85 (m, 4H), 3.95 (ddd, J = 13.9, 
8.6, 5.5 Hz, 1H), 3.89-3.77 (m, 1H), 2.89-2.72 (m, 1H), 2.22-2.16 (m, 3H), 2.16-1.99 (m, 3H), 
1.93-1.80 (m, 1H), 1.71 (d, J = 10.1 Hz, 1H), 1.64-1.50 (m, 2H), 1.34-1.18 (m, 3H) ppm. 13C 
NMR (100 MHz CDCl3) δ 145.4, 127.6, 127.3, 125.4, 122.5, 115.6, 62.2, 57.0, 43.9, 43.1, 
30.8, 30.0, 25.7, 24.2 ppm. LRMS m/z (ES+) m/z: 325 [M+H]+. HRMS (ESI) m/z calcd. for 
C20H25N2S [M +H] 325.1733,  found 325.1735. 
4.1.12.2. 2-Chloro-10-(2-(1-methylpiperidin-2-yl)ethyl)-10H-phenothiazine (13b): Yield: 
38% (19 mg). 1H NMR (400 MHz CDCl3) δ 7.11-7.02 (m, 2H), 6.94 (d, J = 8.3 Hz, 1H), 6.85 
(t, J = 7.4 Hz, 1H), 6.82-6.73 (m, 3H), 3.91-3.78 (m, 1H), 3.78-3.63 (m, 1H), 2.85-2.68 (m, 
1H), 2.14 (s, 3H), 2.07-1.95 (m, 3H), 1.85-1.72 (m, 1H), 1.69-1.58 (m, 2H), 1.56-1.46 (m, 2H), 
1.28-1.11 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 147.5, 145.2, 133.8, 128.4, 128.1, 
127.8, 126.0, 125.1, 123.6, 122.8, 116.8, 116.5, 62.5, 57.1, 44.4, 42.3, 30.9, 29.7, 25.6, 24.1 
ppm. LRMS m/z (ES+) m/z: 359 [M+H]+. HRMS (ESI) m/z calcd. for C20H24ClN2S [M +H] 
359.1343, found 359.1347. 
4.1.12.3. 9-(2-(1-Methylpiperidin-2-yl)ethyl)-9H-carbazole (13c): Yield: 67% (27 mg). 1H 
NMR (400 MHz CDCl3) δ 8.10 (d, J = 7.3 Hz, 2H), 7.52-7.32 (m, 4H), 7.29-7.06 (m, 2H), 
4.52-4.38 (m, 1H), 4.38-4.22 (m, 1H), 2.97-2.82 (m, 1H), 2.33 (s, 3H), 2.17-2.06 (m, 2H), 2.06-
1.94 (m, 2H), 1.79 (d, J = 11.9 Hz, 2H), 1.67-1.60 (m, 2H), 1.40-1.27 (m, 2H) ppm 13C NMR 
(100 MHz CDCl3) δ 140.2, 125.7, 123.0, 120.5, 118.8, 108.6, 61.7, 57.0, 43.0, 39.2, 31.5, 30.7, 
25.6, 24.4 ppm. LRMS m/z (ES+) m/z: 293 [M+H]+. HRMS (ESI) m/z calcd. for C20H24N2 
[M +H], 293.2012 found 293.2014. 
4.1.12.4. 1-(2-(1-Methylpiperidin-2-yl)ethyl)-1H-benzo[d]imidazole (13d): Yield: 70% (29 
mg). 1H NMR (400 MHz CD3OD) δ 8.86 (s, 1H), 8.33-8.22 (m, 2H), 7.99-7.90 (m, 2H), 5.03-
4.95 (m, 2H), 3.55-3.50 (m, 1H), 2.90 (s, 3H), 2.70-2.42 (m, 4H), 2.28-2.24 (m, 2H), 2.00-1.80 
(m, 4H) ppm. 13C NMR (100 MHz CD3OD) δ 144.0, 143.3, 134.0, 123.7, 122.9, 119.6, 110.7, 
62.2, 57.1, 42.1, 32.8, 30.6, 30.1, 25.4, 24.1 ppm. LRMS m/z (ES+) m/z: 244 [M+H]+. HRMS 
(ESI) m/z calcd. for C15H22N3 [M +H] 244.1808, found 244.1811. 
 
4.1.13. Synthesis of 1-(3-chloropropyl)-1H-indole (15) 
Indole (0.52 mmol, 0.052 mL, 1 eq.) was added to 10 mL of DMF in a double neck round 
bottomed flask. NaH (0.57 mmol, 14 mg, 1.1 eq.) was added to the stirring solution at 0 °C, 
and the mixture was allowed to reach r.t stirring for 20 minutes. Then, 1-bromo-3-
chloropropane (0.57 mmol, 90 mg, 1.1 eq.) was added. The reaction mixture was allowed to 
stir under N2 atmosphere for 12h at r.t. The reaction was quenched with water (10 mL) and 
extracted twice with EtOAc (20 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. 
The crude product (15) was purified by chromatography on silica gel, using hexane/EtOAc 
(4:1) as eluent. Yield: 82% (82 mg). 1H NMR (400 MHz CDCl3) δ 7.69 (d, J = 8.0 Hz, 1H), 
7.41 (d, J = 8.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.19-7.15 (m, 2H), 6.56 (d, J = 4.0 Hz, 1H), 
4.37-4.33 (m, 2H), 3.46 (t, J = 8.0 Hz, 1H), 3.32 (t, J = 8.0 Hz, 1H), 2.37-2.26 (m, 2H) ppm. 
13C NMR (100 MHz CDCl3) δ 135.9, 128.8, 128.1, 121.8, 121.2, 119.6, 109.4, 101.6, 42.9, 
42.0, 32.7 ppm. LRMS m/z (ES+) m/z: 194 [M+H]+ 
 
4.1.14. Synthesis of 1-(3-(4-methylpiperazin-1-yl)propyl)-1H-indole (16). 
The derivative 16 was synthesised following the procedure used for the synthesis of compounds 
7a-i. Yield: 63% (30 mg). 1H NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.40 (d, J = 8.0 
Hz, 1H), 7.30-7.24 (m, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.08 (d, J = 12.0 Hz, 2H), 3.24-3.23 (d, J 
= 8.0 Hz, 2H), 2.47 (s, 3H), 2.35 (m, 4H), 1.46-1.41 (m, 4H), 1.32-1.29 (m, 2H) ppm. 13C 
NMR (100 MHz CDCl3) δ 163.7, 138.9, 135.8, 135.7, 132.3, 132.2, 126.7, 126.7, 122.2, 118.0, 
116.2, 56.8, 56.1, 25.2, 24.2, 16.0 ppm. LRMS m/z (ES+) m/z: 258 [M+H]+ HRMS (ESI) m/z 
calcd. for C16H24N3 [M +H] 258.1965, found 258.1966. 
 
4.2 Biology 
Bacterial strains and growth conditions: The bacterial species used in this study were M. 
smegmatis mc2155 (ATCC 700084), M. bovis BCG Pasteur (ATCC 35734), M. tuberculosis 
mc27000, M. tuberculosis H37Rv (ATTC27294), M. tuberculosis CF73 and two MDR-TB 
clinical isolates (CF104 and CF81) obtained from Clemente Ferreira Hospital, Saõ Paulo, 
Brazil.[29] Mycobacterial species were cultured in either Middlebrook 7H9 broth or 
Middlebrook 7H10 agar media supplemented with albumin-dextrose-catalase (ADC) or 
oleic acid-albumin-dextrose-catalase (OADC) enrichments, respectively, purchased from 
BD Biosciences. All reagents were purchased from Sigma-Aldrich unless stated otherwise. 
 
4.2.1. Bacterial growth inhibition assays.  
 
The MIC of the compounds against M. smegmatis mc2155, M. bovis BCG, and M. 
tuberculosis mc27000 were calculated by standard MABA (Microplate Alamar Blue assay) 
as previously described.[27] Briefly, 200 µL of sterile deionized water was added to all 
outer-perimeter wells of a sterile 96-well plate (Corning Incorporated, Corning, NY) to 
minimize evaporation of the medium in the test wells during incubation. The wells in rows 
B to G in columns 3 to 11 received 100 µL of 7H9 medium containing 0.2% casamino acids, 
24 µg/mL pantothenate and 10% OADC (Beckton Dickinson, Sparks, MD). Compounds 
were added to rows B–G followed by 1:2 serial dilutions across the plate to column 10, and 
100 µL of excess medium was discarded from the wells in column 10. The bacterial culture 
at 0.5 McFarland standard diluted 1:50 (100 µL) was added to the wells in rows B to G in 
columns 2 to 11, where the wells in column 11 served as drug-free controls. The plates were 
sealed with parafilmTM and were incubated at 37 °C. A freshly prepared 1:1 mixture of 
Alamar Blue (Celltiter-Blue™, Promega Corp, Madison, WI) reagent and 10% Tween® 80 
(50 µL) and re-incubated at 37 °C for 24 h. 
 
4.2.2. Determination of Minimal Inhibitory Concentration (MIC90) 
 
The anti-M. tuberculosis activity of the compounds against M. tuberculosis H37Rv 
(ATTC27294), M. tuberculosis CF73 and two MDR-TB clinical isolates (CF104 and CF81) 
was determined using the Resazurin Microtiter Assay (REMA) method according to 
Palomino et al., [30]. Stock solutions of the tested compounds were prepared in dimethyl 
sulfoxide (DMSO), then diluted in Middlebrook 7H9 broth (Difco, Detroit, MI, USA) 
supplemented with oleic acid, albumin, dextrose and catalase (OADC enrichment) to obtain 
a final drug concentration range of 0.09–100 µg/mL. A suspension of the M. 
tuberculosis H37Rv ATCC 27294 and clinical isolates were cultured in Middlebrook 7H9 
broth supplemented with OADC and 0.05% Tween 80 for one week at 37 °C in an 
atmosphere of 5% CO2.. The concentration was adjusted at McFarland 1 and diluted to 2.4 
× 105 CFU/mL. 100 µL of the inoculum was added to each well of a 96-well microplate 
together with 100 µL of the compounds. The plate was incubated for 7 days at 37 °C in an 
atmosphere of 5% CO2. After 24 h, 30 µL 0.01% resazurin (solubilized in water) was added. 
The fluorescence of the wells was read after 24 h using a Cytation 3 (BioTek®, Winooski, 
VT, USA). The MIC90 was defined as the lowest concentration resulting in 90% inhibition 
of growth of M. tuberculosis. Samples were set up in three independent assays. 
 
4.2.3. Cytotoxic Analysis (IC50) of MRC-5 cell line 
 
In these experiment, cells were collected in a solution of trypsin/ethylenediamine tetracetic 
acid (EDTA) (Vitrocell®) and centrifuged (252× g for 5 min). The number of cells was 
counted using a Neubauer chamber (Celeromics, Valencia, Spain) after staining non-viable 
cells with 0.4% trypan blue solution (Sigma-Aldrich®) via the cell exclusion assay. Then, 
the cell concentration was adjusted to 7.5 × 104 cells/mL in DMEM for tumor cells and 
MRC-5 cells (ATCC CCL-171). Next, a 200 μL suspension was deposited into each well of 
a 96-well microplate to a cell density of 1.5 × 104 cells/well. The cells were incubated at 37 
°C in an atmosphere of 5% CO2 for 24 h to allow the cells to attach to the plate [31]. The 
compounds were solubilized in DMSO to an initial concentration of 10,000 µg/mL. Test 
solutions of the compounds were prepared to obtain concentrations from 500 to 1.95 μg/mL. 
The diluted solutions were added to the cells after changing the medium to remove any non-
adherent cells, and the cultures were incubated for an additional 24 h. The cytotoxicity of 
the compounds was determined after incubating the cells in 30 μL of resazurin for 
approximately 2 h. The measurement was performed using a Synergy H1 microplate reader 
(BioTek®, Winooski, VT, USA) with excitation and emission filters at wavelengths of 530 
and 590 nm, respectively. The assays were performed in three independent experiments.  
 
4.2.4. Cytotoxicity assay (IC50) of J774 cell line 
 
In vitro cytotoxicity assays (IC50) were performed on the J774 cell line, as previously 
reported.[32] The cells were routinely maintained in Complete Medium (RPMI-1640 
supplemented with 10% heat-inactivated fetal bovine serum (FBS); 100 U/mL penicillin and 
100 μg/mL streptomycin), at 37 °C, in a humidified 5% CO2 atmosphere. After reaching 
confluence, the cells were detached and counted. For the cytotoxicity assay, 
1 × 105 cells/mL were seeded in 200 μL of Complete Medium in 96-well plates (NUNC). 
The plates were incubated at 37 °C under a 5% CO2 atmosphere for 24 h, to allow cell 
adhesion prior to drug testing. The compounds were dissolved in DMSO and subjected to 
two-fold serial dilution from 1250 to 3.9 μg/mL. Cells were exposed to the compounds at 
various concentrations for a 24 h-period. Resazurin solution was then added to the cell 
cultures and incubated for 6 hours. Cell respiration, as an indicator of cell viability, was 
detected by reduction of resazurin to resorufin, whose pink colour and fluorescence indicates 
cell viability. A persistent blue colour of resazurin is a sign of cell death. The fluorescence 
measurements (530 nm excitation filter and 590 nm emission filter) were performed in a 
SPECTRAfluor Plus (Tecan) microfluorimeter. The IC50 value was defined as the highest 
drug concentration at which 50% of the cells are viable relative to the control. 
4.2.5. Efflux pump inhibition assays 
The assay was performed based on previously published protocols.[27] In brief, early log phase 
cells of M. smegmatis were taken and the OD600 was adjusted to 0.4 in 1× PBS. The test samples 
contained (4−6) × 107 bacteria/mL in PBS, 0.4% glucose (as a source of energy for efflux 
pumps activity), 0.5 mg/L ethidium bromide (as a substrate for efflux pumps), and the 
compounds being tested at 1/4× MIC concentrations. Blank samples contained all of the 
components mentioned above, except the bacterial suspension, which was replaced with 1× 
PBS. Verapamil and chlorpromazine, known efflux pump inhibitors, were used as positive 
controls at concentrations of 125 μg/mL and 10 μg/mL respectively. The experiment was 
performed in a 96-well plates that was read in a fluorimeter (FLUOstar OPTIMA, BMG 
Labtech) with the following parameters: wavelengths of 544 and 590 nm for excitation and 
detection of fluorescence, gain 2200, a temperature of 37 °C, and a cycle of measurement every 
minute for a total period of 60 min. The accumulation or efflux of ethidium bromide was 
monitored in real-time for the mentioned period. 
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